ClinicalTrials.gg
RecruitingNCT03686124ACTengineUpdated May 13, 2026

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

A Phase 1/2 interventional study of IMA203 Product and IMA203 product- flat dose in Refractory Cancer, Recurrent Cancer and Solid Tumor, Adult, sponsored by Immatics US, Inc.. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Immatics US, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
375
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

Read the detailed description

SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria including HLA (human leukocyte antigen) screening and a biopsy (or collection of archival tumor tissue) for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of IMA203 or IMA203CD8 product.

MANUFACTURING: IMA203 or IMA203CD8 products will be made from the patients' white blood cells.

TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203/IMA203CD8 product infusion to improve the duration of time that IMA203/IMA203CD8 product stays in the body. The patient will be admitted to the hospital during the T-cell infusion.

After the IMA203/IMA203CD8 product infusion, if applicable, a low dose of IL-2 will be given subcutaneously until day 10.

In Extension Cohort B (IMA203) nivolumab will be administered intravenously.

Patients will be monitored closely throughout the study. The follow-up phase ends 5 years post infusion.

02

Conditions studied

  • Refractory Cancer
  • Recurrent Cancer
  • Solid Tumor, Adult
  • Cancer

Keywords

  • T-cell therapy
  • immunotherapy
  • Melanoma (Skin)
  • Melanoma, Uveal
  • Ovarian Carcinoma
  • Uterine Carcinoma
  • Uterine Carcinosarcoma
  • Immatics
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 375 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Immatics US, Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have recurrent/progressing and/or solid tumors and must have received or not be eligible for all available indicated standard of care treatment.
  • (ECOG) performance status 0-1
  • HLA-A*02:01 positive
  • For patients with ovarian/fallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
  • For patients with endometrial carcinoma only: Patients must have a confirmed diagnosis of recurrent or persistent endometrial carcinoma.
  • according to 1.1
  • Adequate selected organ function per protocol
  • Patient's tumor must express tumor antigen by "IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify.
  • more than 5 months
  • Female patient of must use adequate prior to study entry until 12 months after the infusion of IMA203/IMA203CD8
  • Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203/IMA203CD8
  • The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion.

Exclusion criteria

Exclusion Criteria:

  • History of other (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
  • Pregnant or breastfeeding
  • Serious disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of agents.
  • History of cardiac conditions as per protocol
  • Prior stem cell transplantation or solid organ transplantation
  • Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
  • History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
  • Positive for infection or with active virus (HBV) or active virus (HCV) infection.
  • Patients with LDH greater than 2.0-fold .
  • Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA203/IMA203CD8 treatment
  • Patients with active
  • Concurrent treatment in another clinical trial.
  • For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1/ inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
375 participants (estimated)

Study arms

  • Experimental
    Dose Escalation A (closed to enrollment)

    Dose escalation of IMA203

    Biological: IMA203 Product · Device: IMADetect®

  • Experimental
    Extension Cohort A

    IMA203 at RP2D

    Biological: IMA203 Product · Device: IMADetect®

  • Experimental
    Extension Cohort B (closed to enrollment)

    IMA203 at RP2D + nivolumab

    Biological: IMA203 Product · Drug: Nivolumab

  • Experimental
    Extension Cohort AA

    IMA203 at final RP2D (flat dose)

    Biological: IMA203 product- flat dose · Device: IMADetect®

  • Experimental
    Uveal Melanoma

    IMA203 at RP2D

    Biological: IMA203 Product · Device: IMADetect®

  • Experimental
    Dose Escalation B

    Dose escalation of IMA203CD8

    Biological: IMA203CD8 Product · Device: IMADetect®

  • Experimental
    Extension Cohort C

    IMA203CD8 at dose levels confirmed to be safe

    Biological: IMA203CD8 Product · Device: IMADetect®

  • Experimental
    Extension Cohort D

    IMA203CD8 at dose levels confirmed to be safe; without IL-2

    Biological: IMA203CD8 Product · Device: IMADetect®

  • Experimental
    Ovarian

    IMA203CD8 monotherapy at dose levels confirmed to be safe

    Biological: IMA203CD8 Product · Device: IMADetect®

  • Experimental
    Endometrial

    IMA203CD8 monotherapy at dose levels confirmed to be safe

    Biological: IMA203CD8 Product · Device: IMADetect®

  • Experimental
    Head and Neck, Lung, and Triple Negative Breast Cancer

    IMA203CD8 monotherapy at dose levels confirmed to be safe

    Biological: IMA203CD8 Product · Device: IMADetect®

  • Experimental
    Rare Cancers

    IMA203CD8 monotherapy at dose levels confirmed to be safe

    Biological: IMA203CD8 Product · Device: IMADetect®

Interventions

  • BiologicalIMA203 Product

    The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

    Also known as: anzutresgene autoleucel, anzu-cel

  • The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells

    Also known as: anzutresgene autoleucel, anzu-cel

  • BiologicalIMA203CD8 Product

    The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

  • Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.

    Also known as: Opdivo®

  • DeviceIMADetect®

    IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.

06

What researchers measure

Primary outcomes

  1. Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8

    Number of patients with dose-limiting toxicities (DLTs)

    Time frame: 28 days

  2. Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.

    Treatment emergent adverse events (TEAEs), Adverse events of special interest (AESIs) and Treatment-emergent serious adverse events (TESAEs).

    Time frame: 35 days

  3. Phase 1 and Phase 2: Tumor Response

    Objective response rate (ORR) based on best overall response (BOR) of complete response (CR) and partial response (PR) centrally assessed (by a BICR1) using RECIST1.1

    Time frame: 5 years

Secondary outcomes

  1. Phase 1 and 2: Persistence of TCR engineered T-cells

    Measurement of TCR-engineered T cells in peripheral blood

    Time frame: up to 5 years post treatment

  2. Phase 1 and 2: Tumor response

    Overall response rate, duration of response, disease control rate and progression free survival based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Overall survival.

    Time frame: up to 5 years

  3. Phase 2: Patient reported quality of life

    Quality of Life questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and EuroQol 5-Dimension 5-Level questionnaire). Higher score indicates worsening of patient's condition.

    Time frame: up to 5 years

07

Study locations

21 of 21 sites recruiting
  • Stanford Cancer Institute
    Stanford, California 94305, United States
    Recruiting
  • University of Colorado, Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
    • Sapna Patel, MD · Contact720-848-0000
  • University of Miami Hospital and Clinics
    Miami, Florida 33136, United States
    Recruiting
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • Katherine Kurnit, MD · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Oldadapo O. Yeku, MD. PhD · Contact617-643-6158
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run
    Columbus, Ohio 43026, United States
    Recruiting
  • University of Pennsylvania, Perelamn Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Thomas Jefferson University, Honickman Center
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Diwakar Davar, M.D. · Contactdavard@upmc.edu · 412-623-7368
    • Jason Luke, M.D. · Principal investigator
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Dejka M Araujo, M.D. · Contactdaraujo@mdanderson.org · 713-792-3626
    • Dejka M Araujo, M.D. · Principal investigator
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
  • Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
  • Klinikum rechts der Isar der Technischen Universität München
    Munich, Bavaria 81675, Germany
    Recruiting
  • Universitätsklinikum Würzburg
    Würzburg, Bavaria 97080, Germany
    Recruiting
  • Universitätsklinikum Bonn - Medizinische Klinik III
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
    Recruiting
  • Universitätsklinikum C.-G.-Carus Dresden
    Dresden, Saxony 01307, Germany
    Recruiting
  • Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie
    Berlin, 12203, Germany
    Recruiting
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
    Recruiting
08

References and documents

Publications

  • Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Kursunel MA, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee HG, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2025 Jul;31(7):2365-2374. doi: 10.1038/s41591-025-03650-6. Epub 2025 Apr 9. PubMed 40205198 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2028, 115 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 115 months is above that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2018
First posted
Sep 26, 2018
StartActual
May 14, 2019
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2032
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03686124
Lead sponsor
Immatics US, Inc.
Responsible party
Sponsor
First posted
Sep 26, 2018
Start date
May 14, 2019
Primary completion
Dec 2028 (estimated)
Completion
Jun 2032 (estimated)
Last update
May 13, 2026

Study contacts

Immatics US, Inc.
Contact
ctgovinquiries@immatics.com
+1 346 204-5400
Cedrik Britten, M.D.
study director · Immatics US, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anzutresgene autoleucel

Start the discussion